Susan M. Stalnecker - Jun 2, 2025 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
Director
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Stock symbol
BVS
Transactions as of
Jun 2, 2025
Transactions value $
$0
Form type
4
Date filed
6/4/2025, 09:30 PM
Previous filing
Feb 19, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
STALNECKER SUSAN M Director 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM /s/ Anthony D'Adamio, Attorney-in-Fact 2025-06-04 0001221375

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise $0 +26.5K +33.34% $0.00 106K Jun 2, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -26.5K -100% $0.00 0 Jun 2, 2025 Class A Common Stock 26.5K Direct F1, F2
transaction BVS Restricted Stock Units Award $0 +32.3K $0.00 32.3K Jun 3, 2025 Class A Common Stock 32.3K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 The RSUs vested on June 2, 2025.
F3 The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.